Analysis of Medication Abortion Risk and the FDA report “Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018”

okumi https://blog.hatena.ne.jp/okumi/ リプロな日記 https://okumi.hatenablog.com/ 忘備録 Analysis of Medication Abortion Risk and the FDA report “Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018”概要を試訳しておきます。概要 FDAの報告書「Mifepristone U.S. PostMarketing Adverse Events Summary through 12/31/2018 」には、本剤の使用に関連する有害事象が記載されています。ミフェプリストンと中絶との因果関係の可能性にかかわらず、ミフェプリストンの… 190 <iframe src="https://hatenablog-parts.com/embed?url=https%3A%2F%2Fokumi.hatenablog.com%2Fentry%2F2022%2F06%2F02%2F183719" title="Analysis of Medication Abortion Risk and the FDA report “Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018” - リプロな日記" class="embed-card embed-blogcard" scrolling="no" frameborder="0" style="display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;"></iframe> Hatena Blog https://hatena.blog 2022-06-02 18:37:19 Analysis of Medication Abortion Risk and the FDA report “Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018” rich https://okumi.hatenablog.com/entry/2022/06/02/183719 1.0 100%